Careers  |  Sign In  |  Register

New Standard of Care for Metastatic Renal Cell Carcinoma (mRCC)

Medicine Update

A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was reduced by almost 50% with pembrolizumab plus axitinib,” said study author Thomas Powles, MD, Professor of Urology Oncology at Barts Cancer Institute in London, England. Dr. Powles also added that based on these results, “pembrolizumab and axitinib should be a standard of care in this setting, in my opinion.” The findings were presented at a press briefing held in advance of the Genitourinary Cancers Symposium (GUCS) 2019 in San Francisco.

Learn more by clicking here.